top of page

ASCO Gastrointestinal Cancers Symposium 2022


  • The American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) takes place from January 20-22, 2022 and will be a hybrid model including a virtual aspect as well as in-person portion at Moscone Center in San Francisco, CA

  • The 2022 Gastrointestinal (GI) Cancers Symposium offers new, innovative findings in GI cancer treatment, research, and care.

  • See our Google Sheet HERE that includes extensive info about companies presenting, ongoing clinical trials, and links to poster abstracts.

  • See the full forum article HERE for more information and analysis on this conference after signing up for a subscription. Try free today, learn more here!


Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter


The American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) is taking place in person and online this year from January 20-22, 2022. The in person section will take place at Moscone Center in San Francisco, CA and will include interactive sessions with multidisciplinary perspectives based on the latest research, presentations of new innovations and patient care, and solution focused strategies for the GI cancer care community ( Attendees can stay up to date on the latest GI cancer science, connect with colleagues and presenters, and explore the latest drug developments and technologies. Additionally, the public can use #GI22 to follow along during the symposium on Twitter.

ASCO GI begins at 7am PST on 1/20/22 and continuesthrough 4:30pm PST on 1/22/22. Abstracts became available on 1/18/2022 at 5pm ET after the embargo policy was lifted. Companies could distribute a press release at this time containing full data and any additional or updated data that would be presented, even if not in the abstract. ( CRDF did exactly this when they published a press release involving their CRC program that is being presented at ASCO GI, and their stock dropped 22%. Only eight smid-cap biopharma companies in the database provided a press release reporting their involvement, and CRDF was the only big stock mover when the abstract was released. CRDF announced new data from the KRAS-mutated metastatic colorectal cancer program, and a subset of this will be presented at ASCO GI.

See all ASCO GI abstracts here, and visit our Google Workbook below to see more in depth info on these companies.

Included at ASCO GI are oral abstract sessions, clinical science symposia, poster discussion sessions, poster sessions, and publication only abstracts. Online participants can access a live stream of most meeting sessions as well as online posters and exhibitor directory. All attendees can also access on-demand content.

Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. As experienced biopharma investors understand, the value of a biopharma company is based in large part on the value of its clinical assets. This value takes into account the likelihood of success of the clinical assets of the underlying company in successfully completing clinical trials. An update to a clinical trial that shows some positive results in safety and especially efficacy, can increase the chance of success for that trial, which increases the value of the asset and the underlying company. The converse is true as well, for disappointing results.

Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and approved assets than larger companies, and thus whose valuation can be more affected by a single drug candidate and trial. The clinical assets of these micro, small and mid-cap cancer biopharma companies are a primary driver for the development of future cancer therapies.

With respect to ASCO GI, and biomedical conferences in general, a big challenge for investors is to identify in advance, companies that are reporting significant clinical trial updates at the conference. Many presentations provide less significant information with respect to company valuation (e.g. preclinical results or clinical trial design). At BiopharmIQ (; "BPIQ") we oversee a database of information about clinical assets and their upcoming clinical trial and other catalyst events for virtually every biopharma company with a market cap of between $100M and $5B, which for convenience in this article, we will refer to as smid-cap biopharma companies. Currently, our database has over 550 smid-cap biopharma companies. Our goal at BPIQ is to provide information and education on smid-CAP biopharma companies to level the playing field for all investors, whether retail, professional or institutional.

To this end, our team updated and scoured through our BPIQ database to identify biopharma companies that are presenting at ASCO GI and if new data will be provided. See our Google Sheet HERE that includes extensive info about companies presenting, ongoing clinical trials, and links to poster abstracts.

*Thanks to Maz for his efforts in putting this workbook together. Be sure to follow @Mazeraski on Twitter*

Subscribe to to see the full forum article and Google Sheet HERE and learn more about the smid-cap biopharma companies presenting. Learn more HERE.


If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.

Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!


See what our members are saying about us:

Mike from United States

“Really loving the site over the competitor... like the layout and speed over the the individual pages for each drug/treatment”

Carl from United States

“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”

Essey from Canada

“Love what you’re doing, this website is awesome.”

James from United States

Great site and I see it’s a family run business, great job.”

bottom of page